Cargando…
Clinical Activity of an hTERT-Specific Cancer Vaccine (Vx-001) in “Immune Desert” NSCLC
SIMPLE SUMMARY: We investigated whether there is any correlation between Vx-001 clinical activity and the tumor immune microenvironment (TIME). Our hypothesis was that Vx-001 should be clinically effective in patients with tumor-infiltrating lymphocyte (TIL) negative/low infiltrated (non-immunogenic...
Autores principales: | Pateras, Ioannis S., Kotsakis, Athanasios, Avgeris, Margaritis, Baliou, Evangelia, Kouroupakis, Panagiotis, Patsea, Eleni, Georgoulias, Vassilis, Menez-Jamet, Jeanne, Kinet, Jean-Pierre, Kosmatopoulos, Kostas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037524/ https://www.ncbi.nlm.nih.gov/pubmed/33916194 http://dx.doi.org/10.3390/cancers13071658 |
Ejemplares similares
-
Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial
por: Gridelli, Cesare, et al.
Publicado: (2020) -
Generation of Non-Small Cell Lung Cancer Patient-Derived Xenografts to Study Intratumor Heterogeneity
por: Kanaki, Zoi, et al.
Publicado: (2021) -
A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: Design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients
por: Gallou, Catherine, et al.
Publicado: (2016) -
A Novel Long Non-Coding RNA in the hTERT Promoter Region Regulates hTERT Expression
por: Malhotra, Sanandan, et al.
Publicado: (2017) -
An Improved Model for the hTERT Promoter Quadruplex
por: Chaires, Jonathan B., et al.
Publicado: (2014)